U.S. drug regulators have withdrawn their proposal to regulate over-the-counter CBD, handing the industry another setback after years of delay from the Food and Drug Administration.
The hemp industry has been waiting with bated breath for the release of the U.S. Food and Drug Administration’s Cannabidiol Enforcement Policy Draft Guidance.
Federal food and drug officials said Friday that they plan to fill in current CBD research gaps with “real world data” — but industry advocates are frustrated that regulators haven’t done enough to clear up the rules, which has caused supply-chain bottlenecks while leaving consumers to navigate an increasing field of unregulated products.
Five more CBD manufacturers have received warning letters from the U.S. Food and Drug Administration for making illegal medical claims, with the agency sounding the alarm on Tuesday because of how some of the products are taken — inhaled or dropped in the eyes.
The U.S. Food and Drug Administration (FDA) has asserted its authorityto regulate products derived from cannabis, including hemp, and is therefore playing a major role in the development of markets for hemp derived food, cosmetics and drugs in the United States. This series explores the function and jurisdiction of the FDA in those sectors, how FDA […]
